Yesterday, Sept. 29, 2015, 45 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $447.15 to $2,831,587.72.

Highlighted Stocks Traded by Insiders:

Illumina (ILMN) - FREE Research Report

Klausner Richard, who is Sr VP, Chief Medical Officer at Illumina, sold 423 shares at $173.20 on Sept. 29, 2015. Following this transaction, the Sr VP, Chief Medical Officer owned 24,016 shares meaning that the stake was reduced by 1.73% with the 423-share transaction.

The shares most recently traded at $175.80, up $2.60, or 1.48% since the insider transaction. Historical insider transactions for Illumina go as follows:

  • 4-Week # shares sold: 1,402
  • 12-Week # shares sold: 67,928
  • 24-Week # shares sold: 219,256

The average volume for Illumina has been 1.4 million shares per day over the past 30 days. Illumina has a market cap of $25.4 billion and is part of the health care sector and drugs industry. Shares are down 8% year-to-date as of the close of trading on Tuesday.

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company has a P/E ratio of 51.2. Currently, there are 13 analysts who rate Illumina a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ILMN - FREE

TheStreet Quant Ratings

rates Illumina as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Illumina Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Exponent (EXPO) - FREE Research Report

Johnston Paul R, who is President & CEO at Exponent, sold 4,378 shares at $44.30 on Sept. 29, 2015. Following this transaction, the President & CEO owned 92,862 shares meaning that the stake was reduced by 4.5% with the 4,378-share transaction.

The shares most recently traded at $44.77, up $0.47, or 1.04% since the insider transaction. Historical insider transactions for Exponent go as follows:

  • 4-Week # shares sold: 16,966
  • 12-Week # shares sold: 36,846
  • 24-Week # shares sold: 45,376

The average volume for Exponent has been 110,000 shares per day over the past 30 days. Exponent has a market cap of $1.2 billion and is part of the services sector and diversified services industry. Shares are up 7.98% year-to-date as of the close of trading on Tuesday.

Exponent, Inc., together with its subsidiaries, provides engineering and scientific consulting services worldwide. It operates in two segments, Engineering and Other Scientific; and Environmental and Health. The stock currently has a dividend yield of 1.34%. The company has a P/E ratio of 29.2. Currently, there are no analysts who rate Exponent a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EXPO - FREE

TheStreet Quant Ratings

rates Exponent as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Exponent Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Best Buy (BBY) - FREE Research Report

Vittecoq Gerard R, who is Director at Best Buy, sold 10,974 shares at $36.50 on Sept. 29, 2015. Following this transaction, the Director owned 20,200 shares meaning that the stake was reduced by 35.2% with the 10,974-share transaction.

The shares most recently traded at $36.48, down $0.02, or 0.05% since the insider transaction. Historical insider transactions for Best Buy go as follows:

  • 4-Week # shares sold: 30,185
  • 12-Week # shares sold: 30,985
  • 24-Week # shares sold: 30,985

The average volume for Best Buy has been 4.6 million shares per day over the past 30 days. Best Buy has a market cap of $12.6 billion and is part of the services sector and retail industry. Shares are down 7.72% year-to-date as of the close of trading on Tuesday.

Best Buy Co., Inc. operates as a retailer of technology products, services, and solutions in the United States and internationally. The stock currently has a dividend yield of 2.59%. The company has a P/E ratio of 15.0. Currently, there are 11 analysts who rate Best Buy a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BBY - FREE

TheStreet Quant Ratings

rates Best Buy as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, revenue growth, reasonable valuation levels and good cash flow from operations. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Best Buy Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.